These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act. Arno PS; Bonuck K; Davis M Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947 [TBL] [Abstract][Full Text] [Related]
3. Creation and development of the public service orphan drug Human Botulism Immune Globulin. Arnon SS Pediatrics; 2007 Apr; 119(4):785-9. PubMed ID: 17403850 [TBL] [Abstract][Full Text] [Related]
5. Regulators adopt more orphan drugs. Reardon S Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293 [No Abstract] [Full Text] [Related]
6. The Orphan Drug Act: an engine of innovation? At what cost? Rohde DD Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720 [No Abstract] [Full Text] [Related]
7. Berlex continues legal challenge to FDA over MS drug. Glaser V Nat Biotechnol; 1996 Jul; 14(7):811-2. PubMed ID: 9630997 [No Abstract] [Full Text] [Related]
9. Law and research could add up to profitable niche drugs. Haefner B Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162 [No Abstract] [Full Text] [Related]
11. The Orphan Drug Act. Should it be changed? Sanders CA Arch Intern Med; 1993 Dec; 153(23):2623-5. PubMed ID: 8250658 [No Abstract] [Full Text] [Related]
12. Are orphan product program funds underused by nuclear medicine researchers? Harby K J Nucl Med; 1988 Jun; 29(6):1011-2. PubMed ID: 3373310 [No Abstract] [Full Text] [Related]
13. Orphan products: drugs and devices for rare diseases. Pillar B Nurs Econ; 1993; 11(2):99-102. PubMed ID: 8502310 [TBL] [Abstract][Full Text] [Related]
14. Understanding orphan drug regulations: an EU and U.S. comparative analysis. Grienenberger A J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604 [TBL] [Abstract][Full Text] [Related]
15. Orphan Drug Act on congressional agenda. von Oehsen WH Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123 [TBL] [Abstract][Full Text] [Related]
16. Orphan products development and some methods for maximizing the usefulness of research on rare diseases. Finkel MJ Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285 [No Abstract] [Full Text] [Related]
17. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications--FDA. Notice. Fed Regist; 1998 Aug; 63(150):41855-9. PubMed ID: 10181724 [TBL] [Abstract][Full Text] [Related]
18. The orphan drug backlash. Maeder T Sci Am; 2003 May; 288(5):80-7. PubMed ID: 12701333 [No Abstract] [Full Text] [Related]
19. Lucrative niches: how drugs for rare diseases became lifeline for companies. Anand G Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531 [No Abstract] [Full Text] [Related]
20. Should off-label drug use be off-the-table? Rivkees SA J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432 [No Abstract] [Full Text] [Related] [Next] [New Search]